|Articles|September 21, 2015

HHS to Fund Regeneron's Efforts for Antibody Against Ebola

The collaboration will make available 3 fully-humanized monoclonal antibodies to fight the devastating virus.

The US Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response has entered into an agreement with Tarrytown-based Regeneron Pharmaceuticals, Inc to develop a treatment regimen that includes 3 monoclonal antibodies against the Ebola virus.

The company has developed the 3 fully-humanized monclonal antibodies using their propreitory VelociGene and VelocImmune technologies, and will receive $38 million over a 2-year period for further development and manufacturing of the monoclonal antibodies.

Read the associated press release by HHS here.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

HHS to Fund Regeneron's Efforts for Antibody Against Ebola

Related Content

Targeting Oxidative Stress Could Fill a Gap in the Vitiligo Treatment Toolbox

Simple 3-Marker Index May Flag CKM Syndrome Risk Before Costly Disease Progression

How Hospital Specialty Pharmacies Are Closing the Pharmacy Desert Gap

Patients on GLP-1s Increasingly Carry Diagnoses for New Indications

Lower In-Hospital Mortality Linked to In-Hospital Statin Exposure

Trending on AJMC

Special Report: The Oncology Care Model, 10 Years Later

FDA Approves Tocilizumab-bavi for CAR-T-Induced CRS, Pediatric COVID-19

Weight Loss Drugs Can Improve Outcomes in Patients With Heart Failure and Obesity: Sandra Chaparro, MD

Patients on GLP-1s Increasingly Carry Diagnoses for New Indications

AI Model Challenges Genomic Classifiers in Early Breast Cancer Risk Stratification: Nancy Lin, MD